Artmann Thorsten, Gan Tong Joo, Kranke Peter
Klinik für Anästhesie und Intensivmedizin, Knappschaftskrankenhaus Bottrop GmbH, Bottrop, Deutschland.
Med Klin Intensivmed Notfmed. 2015 Apr;110(2):122-6. doi: 10.1007/s00063-015-0002-6. Epub 2015 Mar 24.
Over the last few decades colloids have played an important part in the stabilisation of patients with acute need of intravascular volume replacement. After the 6S and the CHEST trials were published in 2012 and the subsequent recommendations of the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) there has been some uncertainty about the current clinical relevance and routine use of colloids.
This article summarizes the current evidence and relevance of colloids in the perioperative environment and in the interventional setting on the basis of the recently published German S3-guidelines for volume therapy in adults.
In situations of acute volume resuscitation colloids are still appropriate. Only colloids in balanced solutions should be used. Possible side effects, contraindications and the maximum daily dose have to be taken into consideration when administering colloids.
在过去几十年中，胶体在急需血管内容量替代的患者的液体复苏中发挥了重要作用。2012年6S和CHEST试验发表以及随后欧洲药品管理局（EMA）和美国食品药品监督管理局（FDA）提出建议后，胶体目前的临床相关性和常规应用存在一些不确定性。
本文根据最近发表的德国成人容量治疗S3指南，总结了胶体在围手术期和介入治疗环境中的当前证据及相关性。
在急性容量复苏的情况下，胶体仍然适用。仅应使用平衡溶液中的胶体。使用胶体时必须考虑可能的副作用、禁忌症和每日最大剂量。
